Publication Date
10-1-2023
Journal
Seminars in Perinatology
DOI
10.1016/j.semperi.2023.151817
PMID
37783579
PMCID
PMC10843293
PubMedCentral® Posted Date
10-1-2024
PubMedCentral® Full Text Version
Author MSS
Published Open-Access
yes
Keywords
Infant, Infant, Newborn, Humans, Bronchopulmonary Dysplasia, Infant, Premature, Hypertension, Pulmonary, Lung, Gestational Age, Bronchopulmonary dysplasia, pulmonary hypertension, pathogenesis, diagnosis, management
Abstract
Bronchopulmonary dysplasia (BPD) is the leading cause of chronic lung disease in infants and the commonest complication of prematurity. Advances in respiratory and overall neonatal care have increased the survival of extremely low gestational age newborns, leading to the continued high incidence of BPD. Pulmonary hypertension (PH) represents the severe form of the pulmonary vascular disease associated with BPD, and affects almost one-third of infants with moderate to severe BPD. PH responds suboptimally to pulmonary vasodilators and increases morbidity and mortality in BPD infants. An up-to-date knowledge of the pathogenesis, pathophysiology, diagnosis, treatment, and outcomes of BPD-PH can be helpful to develop meaningful and novel strategies to improve the outcomes of infants with this disorder. Therefore, our multidisciplinary team has attempted to thoroughly review and summarize the latest advances in BPD-PH in preventing and managing this morbid lung disorder of preterm infants.